{"id":"aeras-402-3-x-10-10-vp","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site pain"}]},"_chembl":{"chemblId":"CHEMBL39541","moleculeType":"Small molecule","molecularWeight":"785.11"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AERAS-402 is a recombinant adenovirus vector-based vaccine that aims to induce cellular and humoral immunity against Mycobacterium tuberculosis. This vaccine has been engineered to express the TB10.4 antigen, which is a key component of the M. tuberculosis cell wall.","oneSentence":"AERAS-402 is a vaccine designed to stimulate an immune response against tuberculosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:21:12.634Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis prevention"}]},"trialDetails":[{"nctId":"NCT01198366","phase":"PHASE1, PHASE2","title":"Study of AERAS-402 in Healthy Infants","status":"COMPLETED","sponsor":"Aeras","startDate":"2010-09","conditions":"Tuberculosis","enrollment":487},{"nctId":"NCT01017536","phase":"PHASE2","title":"Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults","status":"COMPLETED","sponsor":"Aeras","startDate":"2009-12","conditions":"Tuberculosis, HIV Infections","enrollment":26},{"nctId":"NCT02414828","phase":"PHASE2","title":"A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB","status":"COMPLETED","sponsor":"Aeras","startDate":"2008-10","conditions":"Tuberculosis","enrollment":72},{"nctId":"NCT02430506","phase":"PHASE1","title":"A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB","status":"COMPLETED","sponsor":"Aeras","startDate":"2008-09","conditions":"Tuberculosis","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AERAS-402"],"phase":"phase_2","status":"active","brandName":"AERAS-402 3 x 10^10 vp","genericName":"AERAS-402 3 x 10^10 vp","companyName":"Aeras","companyId":"aeras","modality":"Biologic","firstApprovalDate":"","aiSummary":"AERAS-402 is a vaccine designed to stimulate an immune response against tuberculosis. Used for Tuberculosis prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}